Roy Beigel

Prof. Dr. Roy Beigel


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2019 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
NFNir Flint
Nir Flint
NWNina C. Wunderlich
Nina C. Wunderlich
HSHezzy Shmueli
Hezzy Shmueli
SBSagit Ben-Zekry
Sagit Ben-Zekry
RSRobert J. Siegel
Robert J. Siegel
RBRoy Beigel
Roy Beigel

1 June 2009 in The American Journal of Cardiology
Verified
Journal Article
Closed access
RBRoy Beigel
Roy Beigel
DODan Oieru
Dan Oieru
OGOrly Goitein
Orly Goitein
PCPierre Chouraqui
Pierre Chouraqui
EKEli Konen
Eli Konen
SMShlomi Matetzky
Shlomi Matetzky

1 December 2014 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
AGAvishay Grupper
Avishay Grupper
RBRoy Beigel
Roy Beigel
EMElad Maor
Elad Maor
RKRafael Kuperstein
Rafael Kuperstein
IHIlan Hai
Ilan Hai
SZSagit Ben Zekry
Sagit Ben Zekry

1 March 2022 in Journal of Cardiology
Verified
Journal Article
Closed access
Amitai SegevAmitai Segev
Amitai Segev
EIEdward Itelman
Edward Itelman
RBRoy Beigel
Roy Beigel
GSGad Segal
Gad Segal
FCFernando Chernomordik
Fernando Chernomordik
AGAvishay Grupper
Avishay Grupper

29 March 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IMIsrael Mazin
Israel Mazin
FCFernando Chernomordik
Fernando Chernomordik
PFPaul Fefer
Paul Fefer
SMShlomi Matetzky
Shlomi Matetzky
RBRoy Beigel
Roy Beigel
It is estimated that in the past two decades the number of patients diagnosed with diabetes mellites (DM) has doubled. Despite significant progress in the treatment of cardiovascular disease (CVD), including novel anti-platelet agents, effective lipid-lowering medications, and advanced revascularization techniques, patients with DM still are least twice as likely to die of cardiovascular causes compared with their non-diabetic counterparts, and current guidelines define patients with DM at the highest risk for atherosclerotic cardiovascular disease and major adverse cardiovascular events (MACE). Over the last few years, there has been a breakthrough in anti-diabetic therapeutics, as two novel anti-diabetic classes have demonstrated cardiovascular benefit with consistently reduced MACE, and for some agents, also improvement in heart failure status as well as reduced cardiovascular and all-cause mortality. These include the sodium-glucose cotransporter-2 inhibitors and the glucagon-like peptide-1 receptor agonists. The benefits of these medications are thought to be derived not only from their anti-diabetic effect but also from additional mechanisms. The purpose of this review is to provide the everyday clinician a detailed review of the various agents within each class with regard to their specific characteristics and the effects on MACE and cardiovascular outcomes.

25 August 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NKNour Karra
Nour Karra
ASAmir Sharon
Amir Sharon
EMEias Massalha
Eias Massalha
PFPaul Fefer
Paul Fefer
EMElad Maor
Elad Maor
IBIsrael M. Barbash
Israel M. Barbash
Background/Objective: Transcatheter aortic valve replacement (TAVR) is indicated for severe aortic stenosis patients with a prohibitive surgical risk. However, its use has been expanding in recent years to include intermediate- and low-risk patients. Thus, registry data describing changes in patient characteristics and outcomes are needed. The aim of this study was to analyse the temporal changes in patient profiles and clinical outcomes of all-comer TAVR. Methods: Baseline characteristics and VARC-3 outcomes of 1632 consecutive patients undergoing TAVR between 2008 and 2021 were analysed. Results: The annual rate of TAVR increased from 30 procedures in 2008–2009 to 398 in 2020–2021. Over the follow-up period, patient age decreased from 85 ± 4 to 80 ± 6.8 (p < 0.001) and the STS score decreased from 5.9% to 2.8% (p < 0.001). Procedural characteristics significantly changed, representing a shift into a minimally invasive approach: adoption of local anaesthesia (none to 48%, p < 0.001) and preference of transfemoral access (74% in 2011–2012 vs. 94.5% in 2020–2021, p < 0.001). The rates of almost all procedural complications decreased, including major vascular and bleeding complications, acute kidney injury (AKI) and in-hospital heart failure. There was a striking decline in rates of complete atrioventricular block (CAVB) and the need for a permanent pacemaker (PPM). PPM rates, however, remain high (17.8%). Thirty-day and one-year mortality significantly declined to 1.8% and 8.3%, respectively. Multivariable analysis shows that AKI, bleeding and stroke are strong predictors of one-year mortality (p < 0.001). Conclusions: The TAVR procedure has changed dramatically during the last 14 years in terms of patient characteristics, procedural aspects and device maturity. These shifts have led to improved procedural safety, contributing to improved short- and long-term patient outcomes.